Rockwell Medical, INC Form 4 insider transactions

Joseph H. Dawson, a Director at Rockwell Medical, Inc., reported transactions involving restricted stock units and a reverse stock split.

Rockwell Medical, Inc. Director Allen Nissenson reported a change in beneficial ownership of common stock, reflecting a 1-for-10 reverse stock split.

Director Joan Lau of Rockwell Medical, Inc. (RMTI) reported a transaction involving common stock, including adjustments for a recent reverse stock split.

Rockwell Medical Director Robert S. Radie acquired 9,633 shares of common stock following a 1-for-10 reverse stock split, increasing his beneficial ownership.

John G. Cooper, a Director at Rockwell Medical, Inc., acquired 9,633 shares of common stock following a 1-for-10 reverse stock split.

Timothy Chole, SVP and CCO of Rockwell Medical, Inc., reported a transaction involving 15,000 shares of common stock on July 1, 2026, following a 1-for-10 reverse stock split.

Rockwell Medical's Chief Operating Officer, Heather Hunter, acquired 15,000 shares of common stock following a 1-for-10 reverse stock split.

Megan C. Timmins, EVP, CLO & Secretary of Rockwell Medical, Inc., reported a transaction involving restricted stock units and common stock following a 1-for-10 reverse stock split.

Jesse Neri, SVP and CFO of Rockwell Medical, Inc., reported transactions involving restricted stock units and common stock following a 1-for-10 reverse stock split.

Mark Strobeck, President and CEO of Rockwell Medical, reports acquisition of 30,000 common stock units.

Rockwell Medical CFO Jesse Neri received a grant of 97,500 performance-based restricted stock units, correcting an omission from a previous filing.

Rockwell Medical filed an amendment to a Form 4 to report a previously omitted grant of 97,500 performance-based restricted stock units to its EVP, CLO and Secretary.

Rockwell Medical filed an amendment to a Form 4 to disclose a previously omitted grant of 85,000 performance-based restricted stock units to its Chief Commercial Officer.

Rockwell Medical CEO Mark Strobeck was granted 352,000 performance-based restricted stock units (PSUs) tied to aggressive stock price appreciation targets.

Rockwell Medical's Chief Operating Officer, Heather Hunter, disposed of 2,444 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Rockwell Medical's EVP, CLO, and Secretary, Megan C. Timmins, reported the withholding of 3,667 common shares to cover tax obligations related to restricted stock unit vesting.

Rockwell Medical's SVP and CFO, Jesse Neri, reported a routine disposition of shares to cover tax obligations related to restricted stock unit vesting.

Rockwell Medical's SVP and CCO, Timothy Chole, reported the disposition of 2,444 common shares to cover tax obligations related to restricted stock unit vesting.

Rockwell Medical's President and CEO, Mark Strobeck, reported a disposition of 7,333 common shares to cover tax withholding obligations related to restricted stock unit vesting.

Rockwell Medical's Chief Operating Officer, Heather Hunter, sold 2,868 shares of common stock at $0.8355 per share on January 2, 2026, under a pre-arranged 10b5-1 trading plan.

Rockwell Medical's SVP and CFO, Jesse Neri, sold 886 shares of common stock on January 2, 2026, under a pre-arranged trading plan.

Rockwell Medical Director Joseph H. Dawson acquired 25,000 common shares and 25,000 stock options, vesting in 2026.

Director John G. Cooper sold 5,079 RMTI shares at $0.87 and now holds 140,372 shares directly.

Rockwell Medical's SVP, Chief Operating Officer, Heather Hunter, sold 2,868 shares of common stock for $1.19 per share, pursuant to a Rule 10b5-1 trading plan.

Rockwell Medical's SVP and CCO, Timothy Chole, sold 2,868 shares of common stock at $1.19 per share pursuant to a pre-arranged 10b5-1 trading plan.

Rockwell Medical's SVP and CFO, Jesse Neri, filed a Form 4 disclosing a future sale of 886 common shares at $1.19 per share, executed under a pre-arranged 10b5-1 trading plan.

Rockwell Medical's President and CEO, Mark Strobeck, sold 6,926 shares of common stock at $1.19 per share as part of a pre-arranged trading plan.

Timothy Chole, SVP and CCO of Rockwell Medical, Inc., amended a Form 4 filing to clarify that his sale of 2,868 shares of common stock on July 1, 2025, was executed under a pre-arranged Rule 10b5-1 trading plan.

Rockwell Medical, Inc.'s President and CEO, Mark Strobeck, filed an amended Form 4 to clarify a pre-planned sale of 6,926 shares of common stock under a Rule 10b5-1 trading plan.

Rockwell Medical's SVP and CFO, Jesse Neri, amended a Form 4 filing to clarify that a scheduled sale of 886 common shares on July 1, 2025, is to be executed under a pre-arranged Rule 10b5-1 trading plan.